Plain-English translation of NCT07101601 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a new medication called , which is designed to treat advanced cancers that haven't responded to other treatments. is a type of drug that works by targeting cancer cell DNA repair. Researchers are studying whether this medication is safe, how well it works, and what dose works best with the fewest side effects.
Many people with advanced cancers need new treatment options when standard therapies stop working. This medication is designed to be gentler on the body's blood cells than older similar drugs, which may help patients tolerate treatment better while still fighting cancer.
You likely qualify if…
You likely don't qualify if…
You would receive the medication by mouth and visit the clinic regularly so doctors can monitor your health, check your tumors, and watch for side effects. The study has two parts: first, researchers will test different doses to find the safest and most effective level, and then a second group will receive that recommended dose. Throughout your participation, you'll have blood tests, imaging scans, and check-ins with your medical team.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
South Korea